Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Váraljai R, et al. Among authors: placke jm. Nat Cancer. 2023 Sep;4(9):1395. doi: 10.1038/s43018-023-00632-w. Nat Cancer. 2023. PMID: 37580519 Free PMC article. No abstract available.
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Váraljai R, et al. Among authors: placke jm. Nat Cancer. 2023 Sep;4(9):1292-1308. doi: 10.1038/s43018-023-00610-2. Epub 2023 Jul 31. Nat Cancer. 2023. PMID: 37525015 Free PMC article.
Early versus late response to PD-1-based immunotherapy in metastatic melanoma.
Lodde GC, Zhao F, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Jansen P, Kowall B, Galetzka W, Hörst F, Kleesiek J, Hellwig B, Rahnenführer J, Rajcsanyi L, Peters T, Hinney A, Placke JM, Sucker A, Paschen A, Becker JC, Livingstone E, Zimmer L, Tasdogan A, Roesch A, Hadaschik E, Schadendorf D, Griewank K, Ugurel S. Lodde GC, et al. Among authors: placke jm. Eur J Cancer. 2024 Oct;210:114295. doi: 10.1016/j.ejca.2024.114295. Epub 2024 Aug 23. Eur J Cancer. 2024. PMID: 39213786 Free article.
The Differential Diagnosis of Leg Ulcers.
Dissemond J, Placke JM, Moelleken M, Kröger K. Dissemond J, et al. Among authors: placke jm. Dtsch Arztebl Int. 2024 Nov 1;(Forthcoming):arztebl.m2024.0133. doi: 10.3238/arztebl.m2024.0133. Online ahead of print. Dtsch Arztebl Int. 2024. PMID: 39115274 Free article. Review.
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.
Jansen P, Galetzka W, Lodde GC, Standl F, Zaremba A, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Placke JM, Landsberg J, Möller I, Sucker A, Paschen A, Hadaschik E, Zimmer L, Livingstone E, Schadendorf D, Ugurel S, Stang A, Griewank KG. Jansen P, et al. Among authors: placke jm. Eur J Cancer. 2024 Sep;208:114208. doi: 10.1016/j.ejca.2024.114208. Epub 2024 Jul 6. Eur J Cancer. 2024. PMID: 39018633 Free article.
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma.
Matull J, Placke JM, Lodde G, Zaremba A, Utikal J, Terheyden P, Pföhler C, Herbst R, Kreuter A, Welzel J, Kretz J, Möller I, Sucker A, Paschen A, Livingstone E, Zimmer L, Hadaschik E, Ugurel S, Schadendorf D, Thielmann CM, Griewank KG. Matull J, et al. Among authors: placke jm. Front Immunol. 2024 Jun 5;15:1383125. doi: 10.3389/fimmu.2024.1383125. eCollection 2024. Front Immunol. 2024. PMID: 38903495 Free PMC article.
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke JM, Krefting F, Zaremba A, Ugurel S, Roesch A, Schulz C, Berking C, Pöttgen C, Menzies AM, Long GV, Dummer R, Livingstone E, Schadendorf D, Zimmer L. Albrecht LJ, et al. Among authors: placke jm. Eur J Cancer. 2024 May;202:113976. doi: 10.1016/j.ejca.2024.113976. Epub 2024 Mar 1. Eur J Cancer. 2024. PMID: 38484692 Free article.
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade.
Chorti E, Kowall B, Hassel JC, Schilling B, Sachse M, Gutzmer R, Loquai C, Kähler KC, Hüsing A, Gilde C, Thielmann CM, Zaremba-Montenari A, Placke JM, Gratsias E, Martaki A, Roesch A, Ugurel S, Schadendorf D, Livingstone E, Stang A, Zimmer L. Chorti E, et al. Among authors: placke jm. Eur J Cancer. 2024 Mar;200:113536. doi: 10.1016/j.ejca.2024.113536. Epub 2024 Jan 18. Eur J Cancer. 2024. PMID: 38306840 Free article.
33 results